Literature DB >> 10753670

The kinetics and magnesium requirements for the folding of antigenomic delta ribozymes.

S Ananvoranich1, J P Perreault.   

Abstract

Using an oligonucleotide hybridization assay to gain insight into the folding of delta ribozymes, we demonstrate a correlation between their folding and catalytic behavior. Together with recent structural information on the crystal structure of self-cleaved genomic delta ribozyme, in which the L3 loop interacts with J1/4 to form the newly proposed stem P1.1, we conclude that it is likely that the P1.1 stem forms only in the presence of Mg(2+). This stem can be detected in both the self-cleaved and trans-acting delta ribozymes. When the trans-acting version of antigenomic delta ribozyme was studied, it is demonstrated that its L3 loop requires magnesium and, apparently, formation of the P1 stem for the subsequently formation of the P1.1 stem. Most importantly, the kinetics were monitored, and provide a significant addition to our understanding of ribozyme tertiary structure formation prior to the chemical cleavage step. Using previous kinetic data and our new findings, we discuss the rate-limiting characteristics of delta ribozyme folding. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10753670     DOI: 10.1006/bbrc.2000.2465

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Kinetic and binding analysis of the catalytic involvement of ribose moieties of a trans-acting delta ribozyme.

Authors:  Karine Fiola; Jean-Pierre Perreault
Journal:  J Biol Chem       Date:  2002-05-15       Impact factor: 5.157

2.  Delta ribozyme benefits from a good stability in vitro that becomes outstanding in vivo.

Authors:  Dominique Lévesque; Sanaa Choufani; Jean-Pierre Perreault
Journal:  RNA       Date:  2002-04       Impact factor: 4.942

3.  Ribozyme-based gene-inactivation systems require a fine comprehension of their substrate specificities; the case of delta ribozyme.

Authors:  Lucien Junior Bergeron; Jonathan Ouellet; Jean-Pierre Perreault
Journal:  Curr Med Chem       Date:  2003-12       Impact factor: 4.530

4.  Cross-linking experiments reveal the presence of novel structural features between a hepatitis delta virus ribozyme and its substrate.

Authors:  Jonathan Ouellet; Jean-Pierre Perreault
Journal:  RNA       Date:  2004-07       Impact factor: 4.942

5.  Gene targeting in the Gram-Positive bacterium Lactococcus lactis, using various delta ribozymes.

Authors:  Karine Fiola; Jean-Pierre Perreault; Benoit Cousineau
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

6.  Examination of the folding pathway of the antigenomic hepatitis delta virus ribozyme reveals key interactions of the L3 loop.

Authors:  Cédric Reymond; Jonathan Ouellet; Martin Bisaillon; Jean-Pierre Perreault
Journal:  RNA       Date:  2006-11-14       Impact factor: 4.942

7.  Monitoring of an RNA multistep folding pathway by isothermal titration calorimetry.

Authors:  Cédric Reymond; Martin Bisaillon; Jean-Pierre Perreault
Journal:  Biophys J       Date:  2009-01       Impact factor: 4.033

8.  Formation of the P1.1 pseudoknot is critical for both the cleavage activity and substrate specificity of an antigenomic trans-acting hepatitis delta ribozyme.

Authors:  Patrick Deschênes; Jonathan Ouellet; Jonathan Perreault; Jean-Pierre Perreault
Journal:  Nucleic Acids Res       Date:  2003-04-15       Impact factor: 16.971

9.  Evidence for ditopic coordination of phosphate diesters to [Mg(15-crown-5)]2+. Implications for magnesium biocoordination chemistry.

Authors:  Elizabeth R Sanchez; M Tyler Caudle
Journal:  J Biol Inorg Chem       Date:  2004-07-07       Impact factor: 3.358

10.  Selection of the most potent specific on/off adaptor-hepatitis delta virus ribozymes for use in gene targeting.

Authors:  Michel V Lévesque; Samuel G Rouleau; Jean-Pierre Perreault
Journal:  Nucleic Acid Ther       Date:  2011-07-08       Impact factor: 5.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.